The role of preclinical PET/SPECT/CT image in translational cancer research and targeted cancer therapies
Cancer is a dynamic disease and becomes heterogeneous during the progression. The heterogeneity of tumor will result in distinct molecular signatures with different degree of sensitivities to the treatments that might be precisely monitored by non-invasive imaging modalities such as PET/SPECT/CT. These imaging results may help us not only knowing more of cancer itself but also may precisely detected the targets of tumors for further effective drug development and patient stratification.
In this webinar, Dr. Pradip Chaudhari, will give insights into how to identify and localize the tumor in the animal model, to characterize the tumor by specific molecular target, to monitor the intricate pathways in tumorigenesis and to evaluate the treatment outcome by non-invasive preclinical PET/SPECT/CT image. These image results are not limited in the preclinical application but may move to the clinical end for further drug development and patient selection.
In Dr. Gabriela Kramer-Marek’s talk, she will address on targeted molecular image in cancer by board range of targeted -PET radiotracer to select patients accuratly, to understand intrinsic resistance mechanisms or the emergence of acquired resistance following treatment initiation and to choose the most effective combination regimen in circumstances in which single-agent therapies are insufficiently effective. These works will enable smart monitoring of immunotherapies and expand opportunities for personalized medicine approaches.
What to expect
Dr. Chaudhari will focus on how to use preclinical PET/SPECT/CT for basic research of cancer biology and anti-cancer drug development. Dr. Kramer-Marek will discuss affibody-based PET agents as potential new imaging biomarkers for personalized assessment of drug resistance and early prediction of patient treatment responses.
- Visualized and quantitatively analyzed the process of intricate pathways in cancer initiation, progression and metastasis by PET/SPECT/CT
- The applications of non-invasive image in translational cancer research and anti-cancer drug development
- Early detection of cancer by immune-PET
- Evaluation the immunotherapy outcome and approaching personalized medicine by immune-PET agent
Who should attend?
The webinar would appeal to basic biologists, radiochemists, clinicians and drug developers interested in the applications of non-invasive image in translational cancer research, cancer immunotherapies and personalized medicine. Researchers in the field of cancer biology and immunotherapy who are interested in immune checkpoint inhibitors would also benefit.
He moved to ACTREC, Tata Memorial Centre in the year 2007 to establish a preclinical imaging department and comparative oncology program. He is actively involved in preclinical PET / SPECT-CT imaging and exploring the utilization of spontaneous cancers of pet animals for basic and translational cancer research. He has been awarded BOYSCAST fellowship from Dept. of Science and Technology to pursue work in radiopharmaceutical research involving animals with spontaneous cancers. He is founder member and past secretary of Laboratory Animal Scientist Association of India, which deals with laboratory animals used in biomedical research. He has several publications to his credit in various areas he has worked in. Besides his academic career, he is an avid nature lover and amateur photographer, who has exhibited his work frequently.